Larasati YA - Search Results

1

Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R.

Larasati YA, Solis GP, Koval A, Griffiths ST, Berentsen R, Aukrust I, Lesca G, Chatron N, Ville D, Korff CM, Katanaev VL. Larasati YA, et al. Cells. 2023 Oct 17;12(20):2469. doi: 10.3390/cells12202469. Cells. 2023. PMID: 37887313 Free PMC article.

2

In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening.

Koval A, Larasati YA, Savitsky M, Solis GP, Good JM, Quinodoz M, Rivolta C, Superti-Furga A, Katanaev VL. Koval A, et al. Among authors: larasati ya. Med. 2023 May 12;4(5):311-325.e7. doi: 10.1016/j.medj.2023.03.001. Epub 2023 Mar 30. Med. 2023. PMID: 37001522 Free article.

3

Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery.

Katanaev VL, Valnohova J, Silachev DN, Larasati YA, Koval A. Katanaev VL, et al. Among authors: larasati ya. Neural Regen Res. 2023 Oct;18(10):2188-2189. doi: 10.4103/1673-5374.369106. Neural Regen Res. 2023. PMID: 37056130 Free PMC article. No abstract available.

4

Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case.

Larasati YA, Thiel M, Koval A, Silachev DN, Koy A, Katanaev VL. Larasati YA, et al. Med. 2024 Aug 13:S2666-6340(24)00305-2. doi: 10.1016/j.medj.2024.07.023. Online ahead of print. Med. 2024. PMID: 39153472 Free article.

5

Clinical and Molecular Profiling in GNAO1 Permits Phenotype-Genotype Correlation.

Lasa-Aranzasti A, Larasati YA, da Silva Cardoso J, Solis GP, Koval A, Cazurro-Gutiérrez A, Ortigoza-Escobar JD, Miranda MC, De la Casa-Fages B, Moreno-Galdó A, Tizzano EF, Gómez-Andrés D, Verdura E, Katanaev VL, Pérez-Dueñas B; Study Group of GNAO1 patients from Spain. Lasa-Aranzasti A, et al. Among authors: larasati ya. Mov Disord. 2024 Sep;39(9):1578-1591. doi: 10.1002/mds.29881. Epub 2024 Jun 16. Mov Disord. 2024. PMID: 38881224

6

GNAO1 Mutations Affecting the N-Terminal α-Helix of Gαo Lead to Parkinsonism.

Solis GP, Larasati YA, Thiel M, Koval A, Koy A, Katanaev VL. Solis GP, et al. Among authors: larasati ya. Mov Disord. 2024 Mar;39(3):601-606. doi: 10.1002/mds.29720. Epub 2024 Feb 15. Mov Disord. 2024. PMID: 38358016

7

Restoration of the GTPase activity and cellular interactions of Gα_o mutants by Zn²⁺ in GNAO1 encephalopathy models.

Larasati YA, Savitsky M, Koval A, Solis GP, Valnohova J, Katanaev VL. Larasati YA, et al. Sci Adv. 2022 Oct 7;8(40):eabn9350. doi: 10.1126/sciadv.abn9350. Epub 2022 Oct 7. Sci Adv. 2022. PMID: 36206333 Free PMC article.

8

The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells.

Meiyanto E, Husnaa U, Kastian RF, Putri H, Larasati YA, Khumaira A, Pamungkas DDP, Jenie RI, Kawaichi M, Lestari B, Yokoyama T, Kato JY. Meiyanto E, et al. Among authors: larasati ya. Adv Pharm Bull. 2021 Jan;11(1):188-196. doi: 10.34172/apb.2021.020. Epub 2020 Nov 7. Adv Pharm Bull. 2021. PMID: 33747866 Free PMC article.

9

The Chemopreventive Activity of Indonesia Medicinal Plants Targeting on Hallmarks of Cancer.

Meiyanto E, Larasati YA. Meiyanto E, et al. Among authors: larasati ya. Adv Pharm Bull. 2019 Jun;9(2):219-230. doi: 10.15171/apb.2019.025. Epub 2019 Jun 1. Adv Pharm Bull. 2019. PMID: 31380247 Free PMC article. Review.

10

Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth.

Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Larasati YA, et al. Sci Rep. 2018 Feb 1;8(1):2039. doi: 10.1038/s41598-018-20179-6. Sci Rep. 2018. PMID: 29391517 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters